Press Releases

3/5/2010
Aureon Laboratories Announces Name Change for Existing Post-Surgical Prostate Cancer Recurrence Test
Commercially available since February 2006, Post-Op Px™ (previously known as Prostate Px), was the first diagnostic test to predict prostate cancer recurrence and disease progression post treatment. For over four years, Post-Op Px has integrated tissue, clinical and molecular information to enable physicians and their patients to make more informed decisions about post-surgical, adjuvant therapies.

1/14/2010
Aureon Laboratories Announces Appointment of New Executive Vice President and CFO
Aureon Laboratories, Inc. today announced the appointment of Robert L. Van Nostrand as Executive Vice President and Chief Financial Officer.

10/13/2009
Aureon Laboratories Announces Hiring of Vice President of Sales
Aureon Laboratories, Inc. today announced the hiring of David Brown as Vice President of Sales. Mr. Brown will provide leadership to the sales team and help oversee the company’s planned expansion into new markets.

8/25/2009
Aureon Laboratories Announces Appointment of New CEO
Aureon Laboratories, Inc., a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, today announced the promotion of Robert Shovlin from the company’s President to President and Chief Executive Officer.

7/8/2009
Study Validates Aureon Technology to Predict Prostate Cancer Disease Progression from Biopsy Tissue
Usage of morphometry and biomarker data key in predicting patient's prostate cancer outcome

12/17/2008
Aureon Laboratories Granted Two U.S. Patents for “Systems Pathology” Approach for Predicting the Occurrence of any Medical Condition
Initial commercial application, Prostate Px®+, provides a personalized prediction of prostate cancer progression at time of diagnosis

8/26/2008
Journal of Clinical Oncology Study Validates Aureon Laboratories’ Systems Pathology Approach for Predicting Prostate Cancer Progression using Prostatectomy Tissue
Aureon Laboratories, a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, today announced that data from a clinical study published in the Journal of Clinical Oncology (JCO) supports the company’s Systems Pathology approach underlying Aureon’s prostatectomy-based test, Prostate Px+.

6/10/2008
M. D. Anderson and Aureon Laboratories to Evaluate Biomarkers Associated with Non-Small Cell Lung Cancer
Aureon Laboratories, Inc. today announced a collaborative research effort with The University of Texas M. D. Anderson Cancer Center

5/19/2008
Aureon Laboratories Introduces Prostate Px®, First Biopsy-Based Test to Predict Prostate Cancer Disease Progression and Recurrence
Prognostic test provides objective information to help physicians and patients make more-informed treatment decisions

1/22/2008
Assessing Therapeutic Response of Prostate Cancer Patients
Aureon Laboratories, Inc. today announced a new phase in a research collaboration with Pfizer, Inc. that shall establish quantitative biometrics for assessing therapeutic response derived from studies focusing on prostate cancer.

10/15/2007
Aureon Laboratories to Collaborate with UCSF on Research Study to Construct Predictive Models for GM-CSF Treatment Response in Patients with Prostate Cancer
Aureon Laboratories, Inc. announced today a research collaboration with the University of California, San Francisco (UCSF) to retrospectively analyze a Phase I clinical trial that examined the effects of neoadjuvant treatment with granulocyte macrophage colony stimulating factor (GM-CSF) prior to radical prostatectomy.

9/6/2007
Aureon Laboratories Completes Initial Study with AstraZeneca Using Predictive Pathology to Stratify Patient Risk for Non-Small Cell Lung Cancer
Aureon Laboratories, Inc. today announced the successful completion of a development project with AstraZeneca designed to identify patients with non-small-cell lung cancer that may benefit from treatment with IRESSA®.

7/16/2007
Improved Prediction of Prostate Cancer Recurrence Through Systems Pathology
Aureon Laboratories and their collaborators announced today the publication of their ‘Systems Pathology’ model for predicting prostate cancer PSA recurrence in the Journal of Clinical Investigation (JCI).

5/2/2006
Aureon Laboratories Awarded Rising Star Award
Aureon Laboratories announced today that it has been awarded the Yonkers Business Week “Rising Star” Award for 2006 by the City of Yonkers.

3/16/2006
Aureon Laboratories Announces New Vice President of Pathology
Aureon Laboratories announced today that Dr. Ricardo Mesa-Tejada has joined as Vice President of Pathology and Medical Director. Dr. Mesa-Tejada has extensive experience in anatomic pathology having served on the faculty at Columbia University where he holds a part-time appointment as Associate Clinical Professor of Pathology, as well as leadership positions with Quest Diagnostics and MetPath/Corning Clinical Laboratories.

2/24/2006
Prostate Px™: Integrated Molecular Test Can Predict Prostate Cancer Recurrence
Aureon Laboratories announced today that it has launched Prostate Px, a unique predictive test that can provide patients and their physicians with a personalized determination of their risk for prostate cancer recurrence following removal of the prostate.